A novel peroxisome proliferator-activated receptor (PPAR)γ agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARγ activation

详细信息    查看全文

• 作者：Takashi Yotsumoto ; Takeshi Naitoh ; Tatsuro Kanaki ; Maho Matsuda ; Nobutomo Tsuruzoe
• 刊名：Metabolism
• 出版年：2003
• 出版时间：December 2003
• 年：2003
• 卷：52
• 期：12
• 页码：1633-1637
• 全文大小：93 K

文摘

NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)γ agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARγ activation. We compared the effect of NIP-222 and another PPARγ agonist, troglitazone, on UAE, plasma glucose level, blood pressure, and creatinine clearance (C_cr) in streptozotocin (STZ)-induced diabetic mice. Treatment for 3 weeks with NIP-222 (30 mg/kg) was associated with a significant decrease in UAE without any change in blood pressure, creatinine clearance, or plasma glucose level. In contrast, UAE did not decrease in mice treated with troglitazone (300 mg/kg). These results indicate that NIP-222 has PPARγ independent effects on UAE in diabetic mice and suggest that this agent may have potential to minimize the development and progression of diabetic nephropathy.